It costs a lot to install and run one of these trials and they are running a lot for some really big names. By the time a deal is struck it's going to be too late to buy in.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025